1.1 什么是Adoptive T-cell therapy(过继性T细胞疗法)? 过继性T细胞疗法(Adoptive T-cell therapy, ACT)是一种利用患者自身T细胞来治疗恶性肿瘤的细胞免疫疗法。ACT的核心是将患者体内的T细胞分离出来,在体外进行扩增、基因改造或激活,以增强其抗肿瘤能力,然后再回输到患者体内。ACT主要包括以下几种方法: 肿瘤浸润性...
Figure 1 The structure of CAR and the mechanism of CAR-T cell therapy 图2 CAR-T细胞治疗血液系统恶性肿瘤常用靶点 CAR-T细胞治疗常用靶点包括针对髓细胞性血液系统恶性肿瘤的CD123、针对T细胞性血液系统恶性肿瘤的CD7、针对多发性骨髓瘤的BCMA、针对B-ALL/B-NHL的CD19. CAR:嵌合抗原受体;BCMA:B细胞成熟抗...
Multiple myeloma (MM) remains a challenging hematologic malignancy despite advancements in chimeric antigen receptor T-cell (CAR-T) therapy. Current targets of CAR-T cells used in MM immunotherapy have limitations, with a subset of patients experiencing antigen loss resulting in relapse. Therefore, ...
Single structure from the CD3 ζ- chain or FcεRIγ from the intracellular domain for the first generation of CARs is the typical characteristics, which is the primary transmitter of signals from endogenous T cell receptor (TCR) [5, 6]. However, these CAR-T cells could not produce enough...
The structure of BBIR CAR and SUPRA CAR -02- CAR-T细胞疗法的临床进展 目前,CAR-T细胞被广泛应用于肿瘤治疗,尤其是血液恶性肿瘤。据统计,全球已经批准了多达300 个以上的CAR-T 细胞治疗临床试验,数据显示,CAR-T 疗法总体显示是有效的,且有...
scFv to the transmembrane structure and allows the antigen-binding structural section to overcome the spatial site barrier to reach the targeting epitope [9]. The intracellular domain has a direct impact on the CAR-activated T-cell effect, making it the most critical component of the CAR-T stru...
Basics of CAR T-cells CAR T-cell product heterogeneity is affected by CAR structure [24,25,26], T cell subtype [27] and product manufacturing process [28], which influences the efficacy and safety of CAR T-cell therapy. Single-cell sequencing technologies can systematically evaluate the impact...
CAR-T细胞疗法的全称是chimeric antigen receptor T cell therapy,即嵌合抗原受体T细胞疗法,原理是应用患者自身的T淋巴细胞,经过实验室重新改造,装载上具有识别肿瘤抗原的受体及共刺激分子,体外扩增后再次回输入患者体内,从而识别并攻击自身的肿瘤细胞。2014年,CAR-T细胞治疗已在急性淋巴细胞白血病(ALL)中取得显著疗效,...
2022年8月18日,牛津大学和法兰克福大学学者在 Cell 上联合发表了研究论文Structure of a fully assembled tumor-specific T cell receptor ligated by pMHC。 该研究利用冷冻电子显微镜等技术,首次描述了肿瘤特异性T细胞受体与激活配体结合时的结构。让研究者感到意外的是,与其他受体不同,T细胞受体在激活时并不会改变其...
在抗原非依赖性强直信号传导验证方面,Adiect公司发布的关于同种异体 CD20 靶向 γδ T 细胞的研究中,证明了CD20 CAR 仅在细胞表面表达,CAR相关磷酸化 CD3ζ仅在 CAR 刺激后检测到,不会在 Vδ1 γδ T 细胞中诱导抗原非依赖性强直信...